Vesigel is under clinical development by UroGen Pharma and currently in Phase III for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase III drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Vesigel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vesigel overview
VesiGel is under development for the treatment of low-grade intermediate risk non muscle invasive bladder cancer (NMIBC). VesiGel is a sustained release formulation of a high dose mitomycin C. It is administered through intravesical route as a solution. It acts by targeting DNA. It is developed based on reverse thermally triggered hydrogel (RTGel) platform technology.
UroGen Pharma overview
UroGen Pharma, formerly TheraCoat, is a biopharmaceutical company that develops novel medicines to treat cancer indications and urologic diseases. The company products include Jelmyto is a drug formulation of mitomycin used to treat low-grade upper tract urothelial cancer. Its pipeline products include UGN-102 is a mitomycin gel is used to treat low-grade intermediate risk non-muscle invasive bladder cancer; UGN-201 and UGN-302 targets high-grade non-muscle invasive bladder cancer and Botox or RTgel for the treatment of overactive bladder. UroGen Pharma designed RTGel a reverse-thermal hydrogel technology platform to facilitate intracavitary treatment of urological conditions. The company works in collaboration with Allergan and Janssen pharmaceuticals to advance its pipeline products. UroGen Pharma is headquartered in Princeton, New Jersey, the US.
For a complete picture of Vesigel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
